| Belgrade Family Dental | |
|
500 Borgerding Ave Belgrade MN 56312-4533 | |
| (320) 293-5380 | |
| Not Available |
| Full Name | Belgrade Family Dental |
|---|---|
| Speciality | Dentist - General Practice |
| Location | 500 Borgerding Ave, Belgrade, Minnesota |
| Authorized Official Name and Position | Chris Mcgrew (CEO) |
| Authorized Official Contact | 3202935380 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Belgrade Family Dental Po Box 68 Pierz MN 56364-0068 Ph: () - | Belgrade Family Dental 500 Borgerding Ave Belgrade MN 56312-4533 Ph: (320) 293-5380 |
| NPI Number | 1154611200 |
|---|---|
| Provider Enumeration Date | 04/11/2011 |
| Last Update Date | 04/11/2011 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154611200 | NPI | - | NPPES |
| 629412100 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | D12231 (Minnesota) | Primary |
News Archive
AirPal, a medical device manufacturer headquartered in North Wales, Pennsylvania, has received notification of allowance from the U.S. Patent Office for its modular system of inflatable devices used to position patients for situations such as difficult airway management, laryngoscopies, diagnostic exams, surgeries, and related procedures.
The Healthcare Information and Management Systems Society has asked HHS to give the Certification Commission for Healthcare Information Technology authorization to determine which electronic health records systems can receive funding from the economic stimulus package, the Washington Post reports. In a letter dated April 27 to HHS officials, HIMSS officials wrote, "To ensure continuity, recognize CCHIT as the certifying body" of EHRs.
A diagnostic tool developed by Rice University scientists to detect heart attacks using a person's saliva is being tested at the Michael E. DeBakey VA Medical Center in collaboration with Baylor College of Medicine in Houston.
Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries.
› Verified 7 days ago